EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity

Olga N Alekseeva iD, Pavel O Vorobyev iD, Yasmin Shakiba iD, Stepan A Ionov, Svetlana S Antseva, Anastasia V Semenova, Marat P Valikhov iD, Vladimir A Kalsin, Veronika V Vadekhina iD, Dmitry V Kochetkov, Peter M Chumakov iD, Anastasia V Poteryakhina

International Journal of Molecular Sciences · 28.06.2026 · 27 (13) · 5838

DOI: 10.3390/ijms27135838 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.06.2026. Verfasst von Olga N Alekseeva und 11 weiteren Autor:innen. Beteiligte Einrichtung: Engelhard Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Vaccinia virus, Oncolytic Virotherapy, Thymidine Kinase, Oncolytic Viruses. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, The Ministry of Education and Science of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic virotherapy offers a promising avenue for solid tumor treatment, yet single-agent approaches are frequently limited by insufficient tumor lysis and inadequate immune activation. Here we report that combined therapy with two recombinant variants of the oncolytic vaccinia virus, armed with either herpes simplex virus thymidine kinase (VV-HSVtk) or the interleukin 15 receptor subunit alpha (VV-mIL15Rα), leads to enhanced cytotoxicity and immune stimulation in a murine mammary adenocarcinoma model (4T1). In vitro, VV-HSVtk exhibited dose-dependent cytotoxicity markedly potentiated by ganciclovir (GCV) through HSVtk-mediated phosphorylation into a cytotoxic nucleoside analog, and co-culture of VV-infected tumor cells with donor-derived NK cells further increased oncolytic efficiency. In vivo, combined treatment with VV-HSVtk, VV-mIL15Rα, and GCV resulted in significant tumor regression and extended survival relative to monotherapy controls in 4T1 syngeneic mice. Histological examination revealed increased lymphocytic infiltration at tumor sites and absence of hepatic or splenic toxicity. Together, these data indicate that integrating direct viral cytotoxicity, HSVtk/GCV-mediated suicide gene therapy, and IL-15-pathway-targeted immunomodulation within an oncolytic vaccinia platform can improve antitumor efficacy in a stringent breast cancer model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccinia virusOncolytic VirotherapyThymidine KinaseOncolytic VirusesInterleukin-15 Receptor alpha SubunitAnimalsFemaleMiceCell Line, TumorGanciclovirKiller Cells, NaturalSimplexvirusMice, Inbred BALB CHumans

Stichwörter der Autor:innen

interleukin 15oncolytic virusthymidine kinasevaccinia virus

Substanzen

Thymidine KinaseInterleukin-15 Receptor alpha SubunitGanciclovir

Autor:innen und Institutionen

  • Engelhard Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia.
  • Moscow Center for Advanced Studies, Kulakova Str. 20, 123592 Moscow, Russia.
  • Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical and Biological Agency, 115682 Moscow, Russia.
  • Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
  • Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, 117997 Moscow, Russia.

ORCID-Profile: Olga N Alekseeva, Pavel O Vorobyev, Yasmin Shakiba, Marat P Valikhov, Veronika V Vadekhina, Peter M Chumakov

Förderung

  • Russian Science Foundation
  • The Ministry of Education and Science of the Russian Federation

Zitieren

APA

Alekseeva, O. N., Vorobyev, P. O., Shakiba, Y., Ionov, S. A., Antseva, S. S., Semenova, A. V., Valikhov, M. P., Kalsin, V. A., Vadekhina, V. V., Kochetkov, D. V., Chumakov, P. M., & Poteryakhina, A. V. (2026). Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity. International Journal of Molecular Sciences, 27(13), 5838. https://doi.org/10.3390/ijms27135838

Vancouver

Alekseeva ON, Vorobyev PO, Shakiba Y, Ionov SA, Antseva SS, Semenova AV, et al. Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity. International Journal of Molecular Sciences. 2026;27(13):5838. doi:10.3390/ijms27135838

BibTeX
@article{Alekseeva2026,
  author = {Alekseeva, Olga N and Vorobyev, Pavel O and Shakiba, Yasmin and Ionov, Stepan A and Antseva, Svetlana S and Semenova, Anastasia V and Valikhov, Marat P and Kalsin, Vladimir A and Vadekhina, Veronika V and Kochetkov, Dmitry V and Chumakov, Peter M and Poteryakhina, Anastasia V},
  title = {Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {13},
  pages = {5838},
  doi = {10.3390/ijms27135838}
}
Kostenlos starten →